PM360

APRIL 22, 2024

In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience.

Education 59

Education Physicians Healthcare Healthcare 59

Clarivate

MAY 14, 2024

While initially developed to help regulate blood sugar levels, they have also been found to promote appetite suppression, leading to weight loss in patients. What’s leading to the boom in development of semaglutide biosimilars? Contact us to learn more about the Mainland China healthcare market and disease-specific trends.

Manufacturing 52

Manufacturing Marketing Leads Medicine 52

Clarivate

OCTOBER 25, 2021

This year, Clarivate acquired Bioinfogate , a leading provider of analytics solutions in the life sciences and producer of the OFF-X portal. OFF-X is already integrated with several Cortellis products, including Cortellis Drug Discovery Intelligence and Cortellis Competitive Intelligence.

Safety 110

Safety Biopharma Competition Management 110

Clarivate

DECEMBER 6, 2022

In a fiercely competitive U.S. healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. Christopher Silva, Senior Healthcare Research Analyst.

Networking 52

Networking Healthcare Healthcare Competition 52

European Pharmaceutical Review

DECEMBER 19, 2022

1 However, as most biosimilars are developed by means of a complex biotechnological process in living organisms, this inevitably leads to differences between the biosimilar and the reference product. Marie Manley leads Sidley’s Life Sciences team in London and is a distinguished thought leader and adviser on EU and UK regulatory law.

Medicine 52

Medicine Biopharma Safety Food 52

Clarivate

OCTOBER 25, 2023

exclusions exist for orphan drug designation and biosimilar competition ). However, the ultimate impact of this program should have far-reaching effects for pharmaceutical companies and the broader healthcare system that bear monitoring as the IRA’s multi-year implementation schedule unfolds.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

PM360

AUGUST 9, 2022

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. Innovation Is Expanding, But Healthcare Systems Are Slow to Adapt. Driving scale in a slow-moving healthcare ecosystem is not just a challenge for cell and gene therapies.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

Clarivate

JANUARY 23, 2024

She has over 19 years of experience within Pharmaceutical R&D analytics and currently leads a broad array of assignments including Pharma R&D industry benchmarking, competitive landscape analysis and building business intelligence platforms within the R&D development space.

Pharma 52

Pharma Sales Consulting Pharmaceutical 52

Clarivate

OCTOBER 19, 2023

Clarivate leads two subscription-based pre-competitive consortia for Algorithm Benchmarking (ABC) and Computational Biology for Drug Discovery (CBDD) , where Clarivate benchmarks and implements advanced state-of-the-art pathway and network analysis algorithms that have a direct application in drug discovery and development.

Networking 59

Networking Consulting Safety Side effects 59

PM360

SEPTEMBER 28, 2022

At Roche at the time, his job was to lead a task force which was given the objective of planning a strategy to preserve and protect the companies billion-dollar originator biologics franchises as well as build a plan which would counter the introduction and use of biosimilars. Now, as the President of Accord BioPharma , the U.S.

Competition 98

Competition Marketing Biopharma Manufacturing 98

Clarivate

OCTOBER 10, 2022

Fruquintinib will face fierce competition should it be approved in the third- and later-line setting. The question of which KRAS inhibitor is most effective remains elusive, although being first to market in addition to strong efficacy and safety data could differentiate the more competitive agent. References. [1]

Marketing 52

Marketing Safety Patients Competition 52

Veeva

APRIL 28, 2024

As the pharmaceutical landscape grows more dynamic and competitive, life sciences companies are increasingly expected to develop more innovative brand launches, whilst juggling more complexity in marketing and interactions with healthcare professionals (HCPs).

Management 52

Management Marketing Distribution Biopharma 52

European Pharmaceutical Review

DECEMBER 21, 2022

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. Production and value creation can be regionalised and decentralised, which could lead to a more resilient economic structure. The path to real zero.

Manufacturing 75

Manufacturing Pharmaceutical Healthcare Healthcare 75

European Pharmaceutical Review

DECEMBER 26, 2023

1 As revolutionary upstream and downstream technologies become a reality, biopharma companies will need to determine how best to integrate them into their current systems. 2 Capabilities in suspension cell lines and proprietary cell lines are becoming increasingly important to competitiveness within the gene therapy industry.

Manufacturing 84

Manufacturing Safety Patients Competition 84

Pharmaceutical Technology

JANUARY 25, 2023

In December 2022, AEON Biopharma, a biopharmaceutical company, announced its plans to go public through a merger with the SPAC Priveterra Acquisition Corp. Morgan Healthcare Conference in San Francisco, which finished on January 12. But such areas are highly competitive. Download our free whitepaper.

Marketing 69

Marketing Biopharma Pharma Competition 69

Clarivate

DECEMBER 14, 2023

Pharmaceutical benefit managers, M&A activity among integrated delivery networks, disruption by nontraditional healthcare entities, enrollment, and the 2024 presidential election are five areas to pay attention to moving into 2024. Clarivate experts explain why these topics are ones to watch in 2024.

Marketing 52

Marketing Healthcare Healthcare Insurance 52